M&G Plc Sells 1,571 Shares of Illumina, Inc. (NASDAQ:ILMN)

M&G Plc reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 146,383 shares of the life sciences company’s stock after selling 1,571 shares during the period. M&G Plc owned 0.09% of Illumina worth $19,030,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Industrial Alliance Investment Management Inc. bought a new position in shares of Illumina in the second quarter worth approximately $34,000. Versant Capital Management Inc boosted its stake in Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the last quarter. Massmutual Trust Co. FSB ADV increased its holdings in shares of Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares in the last quarter. Focused Wealth Management Inc purchased a new position in shares of Illumina in the third quarter worth $63,000. Finally, nVerses Capital LLC bought a new position in shares of Illumina during the third quarter valued at $65,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Up 2.2 %

Shares of Illumina stock opened at $155.15 on Friday. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market capitalization of $24.72 billion, a P/E ratio of -15.58 and a beta of 1.13. The company has a fifty day moving average of $137.27 and a 200 day moving average of $123.12.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 6.36% and a negative net margin of 36.10%. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same period in the previous year, the business earned $0.33 earnings per share. The business’s revenue was down 3.5% on a year-over-year basis. On average, sell-side analysts anticipate that Illumina, Inc. will post 3.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday. Daiwa America raised shares of Illumina to a “strong-buy” rating in a report on Friday, August 16th. TD Cowen raised their price target on shares of Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday. Royal Bank of Canada raised their price target on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Scotiabank dropped their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $162.18.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.